Jennifer Buckley

Saint Luke's Hospital

Papers

1

Total Citations

9

H-Index

1

About

Jennifer Buckley is a clinician-researcher whose work bridges the frontiers of precision oncology and minimally invasive surgical oncology. Her primary research focuses on the molecular mechanisms driving treatment resistance in colorectal and esophageal cancers, with a particular emphasis on actionable mutations like EGFR T790M. In her landmark 2023 case report—cited 9 times—Buckley demonstrated that osimertinib, a third-generation EGFR inhibitor typically reserved for lung cancer, can elicit a meaningful response in a colorectal cancer patient harboring the T790M mutation. This finding challenges entrenched tumor-site silos and opens new avenues for repurposing targeted therapies. Beyond molecular oncology, Buckley is a leading advocate for the adoption of robotic and thoracoscopic approaches in esophagectomy, a notoriously complex procedure with a steep learning curve. She has published extensively on how enhanced visualization and precision in minimally invasive surgery can reduce morbidity without compromising oncologic outcomes. Her dual expertise—decoding resistance pathways at the bench while refining surgical techniques at the bedside—positions her as a translational bridge-builder. Buckley’s work is reshaping how we think about both targeted therapy in colorectal cancer and the safe expansion of minimally invasive esophageal surgery.

Research Focus

Key Achievements

1
H-Index
1
Papers
9
Total Citations
9
Avg Citations/Paper
🏆 Most Cited Paper
Response to osimertinib in a colorectal cancer patient with an <i>EGFR</i> T790M mutation: A case report
9 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Saint Luke's Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago